Sotera Health CO SHC
We take great care to ensure that the data presented and summarized in this overview for Sotera Health Co is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SHC
View all-
Warburg Pincus LLC New York, NY73.8MShares$861 Million73.2% of portfolio
-
Gtcr LLC49.2MShares$574 Million64.75% of portfolio
-
Darsana Capital Partners LP New York, NY20MShares$233 Million8.48% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.9MShares$174 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$133 Million0.0% of portfolio
-
Sachem Head Capital Management LP New York, NY7.91MShares$92.2 Million7.64% of portfolio
-
Janus Henderson Group PLC London, X07.78MShares$90.7 Million0.06% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD7.59MShares$88.6 Million0.06% of portfolio
-
Sessa Capital Im, L.P. New York, NY6.3MShares$73.5 Million3.3% of portfolio
-
Mig Capital, LLC Newport Beach, CA5.92MShares$69 Million9.16% of portfolio
Latest Institutional Activity in SHC
Top Purchases
Top Sells
About SHC
Sotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries. It serves medical devices; pharmaceuticals; food and agricultural products; and commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2017 and is headquartered in Broadview Heights, Ohio.
Insider Transactions at SHC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 03
2025
|
Michael B. Petras Jr. Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
298,953
+25.61%
|
-
|
|
Mar 03
2025
|
Jonathan M. Lyons Sr. Vice President, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
97,159
+21.21%
|
-
|
|
Mar 03
2025
|
Michael P Rutz President of Sterigenics |
BUY
Grant, award, or other acquisition
|
Direct |
48,579
+7.77%
|
-
|
|
Mar 03
2025
|
Alexander Dimitrief SVP, General Counsel and Sec. |
BUY
Grant, award, or other acquisition
|
Direct |
56,053
+14.34%
|
-
|
|
Mar 02
2025
|
Michael B. Petras Jr. Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
72,859
-5.84%
|
$874,308
$12.47 P/Share
|
|
Mar 02
2025
|
Michael B. Petras Jr. Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
27,990
-4.17%
|
$335,880
$12.47 P/Share
|
|
Mar 02
2025
|
Jonathan M. Lyons Sr. Vice President, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,481
-5.87%
|
$77,772
$12.47 P/Share
|
|
Mar 02
2025
|
Michael P Rutz President of Sterigenics |
SELL
Payment of exercise price or tax liability
|
Direct |
9,597
-0.9%
|
$115,164
$12.47 P/Share
|
|
Mar 02
2025
|
Michael P Rutz President of Sterigenics |
SELL
Payment of exercise price or tax liability
|
Direct |
3,687
-0.68%
|
$44,244
$12.47 P/Share
|
|
Mar 02
2025
|
Alexander Dimitrief SVP, General Counsel and Sec. |
SELL
Payment of exercise price or tax liability
|
Direct |
8,211
-2.86%
|
$98,532
$12.47 P/Share
|
|
Nov 22
2024
|
Michael B. Petras Jr. Chairman & CEO |
BUY
Bona fide gift
|
Indirect |
39,243
+50.0%
|
-
|
|
Nov 22
2024
|
Michael B. Petras Jr. Chairman & CEO |
SELL
Bona fide gift
|
Indirect |
39,243
-0.75%
|
-
|
|
Nov 20
2024
|
Michael B. Petras Jr. Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
29,250
-4.18%
|
$380,250
$13.21 P/Share
|
|
Nov 20
2024
|
Michael P Rutz President of Sterigenics |
SELL
Payment of exercise price or tax liability
|
Direct |
2,889
-0.53%
|
$37,557
$13.21 P/Share
|
|
Sep 10
2024
|
Michael B. Petras Jr. Chairman & CEO |
SELL
Bona fide gift
|
Indirect |
200,000
-3.67%
|
-
|
|
Sep 06
2024
|
Warburg Pincus & Co. Director |
SELL
Open market or private sale
|
Indirect |
30,000,000
-16.89%
|
$450,000,000
$15.03 P/Share
|
|
Sep 06
2024
|
Gtcr Investment Xi LLC Director |
SELL
Open market or private sale
|
Indirect |
10,000,000
-16.89%
|
$150,000,000
$15.03 P/Share
|
|
Aug 05
2024
|
Jonathan M. Lyons Sr. Vice President, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,659
-6.49%
|
$107,226
$14.22 P/Share
|
|
May 24
2024
|
Karen Flynn |
BUY
Grant, award, or other acquisition
|
Direct |
20,089
+50.0%
|
-
|
|
May 24
2024
|
Robert Brown Knauss |
BUY
Grant, award, or other acquisition
|
Direct |
20,089
+35.94%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 702K shares |
|---|---|
| Bona fide gift | 39.2K shares |
| Payment of exercise price or tax liability | 169K shares |
|---|---|
| Bona fide gift | 239K shares |
| Open market or private sale | 40M shares |